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DJ-1 is a multifunctional protein that plays an important role in oxidative stress, cell death, and
synucleinopathies, including Parkinson disease. Previous studies have demonstrated that total DJ-1 levels
decrease in the cerebrospinal fluid, but do not change significantly in human plasma from patients with
Parkinson disease when compared with controls. In this study, we measured total DJ-1 and its isoforms in
whole blood of patients with Parkinson disease at various stages, Alzheimer disease, and healthy controls to
identify potential peripheral biomarkers of PD. In an initial discovery study of 119 subjects, 7 DJ-1 isoforms
were reliably detected, and blood levels of those with 4-hydroxy-2-nonenalmodifications were discovered to
be altered in late-stage Parkinson disease. This result was further confirmed in a validation study of another
114 participants, suggesting that, unlike total DJ-1 levels, post-translationally modified isoforms of DJ-1
from whole blood are candidate biomarkers of late-stage Parkinson disease.
P
arkinson disease (PD) is a chronic, progressive movement disorder that is the second most common
neurodegenerative disease after Alzheimer disease (AD)1. Recent epidemiologic data estimates overall
PD prevalence to be approximately 1.6% among people 65 years of age or older, although prevalence rates
among some combinations of ethnicity, gender, and geographic location are observed to be much higher in the
elderly population2. Although PD was first described nearly 200 years ago, its pathogenic mechanisms remain
unclear. Currently, PD diagnosis is essentially based upon patient medical history, along with observation of the
cardinal motor indicators of the illness and drug treatment effects3. However, there is an appreciablemisdiagnosis
rate4 and there is no established way of objectively monitoring disease progression. Thus, biomarkers are sorely
needed to aid in both the diagnosis and in monitoring the severity/progression of PD. To date, one of the most
extensively tested markers in human cerebrospinal fluid (CSF) is DJ-15, in which mutation causes autosomal
recessive PD6 and is also believed to be important in idiopathic PDparticularly due to its antioxidative activity and
associated neuroprotection7. However, accessing CSF is not a trivial task in a regular clinical setting, let alone in a
screening assay that can be used for early-stage diagnosis.
In contrast to CSF, blood is amuchmore readily accessible source for clinical application and is widely used for
measuring biomarkers in a variety of illnesses8–11. It has been reported that plasmaDJ-1 levels do not significantly
differ between controls and patients with PD or AD12. However,.95% of blood-based DJ-1 is contained within
red blood cells (RBCs)12 and the levels of total DJ-1 and its isoforms, including those with post-translational
modifications (PTMs), are still unknown in whole blood samples of PD patients and controls. In this study, we
began by assessing the total amount of DJ-1 and levels of its isoforms among PD, AD, and control blood using a
combination of one- or two-dimensional gel electrophoresis (2-DE) with quantitative western blot analysis to
provide clues for the development of a PD biomarker screen in human blood samples. DJ-1 isoforms with PTMs
were evaluated with mass spectrometry (MS), and novel isoforms discovered to be modified with 4-hydroxy-2-
nonenal (4-HNE) were further investigated as potential biomarkers of PD diagnosis as well as disease severity.
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Results
Total DJ-1 amount in PD vs. control blood samples. Since a
majority of total DJ-1 is attributable to RBCs, we evaluated the
potential use of DJ-1 in whole blood as a biomarker of PD. To
accomplish this goal, a total of 119 participants in the discovery set
were separated into 5 diagnostic sets and classified as controls, AD
patients, and early-, middle- or late-stage PD patients according to
Unified Parkinson Disease Rating Scale (UPDRS) score (Table 1).
Total DJ-1 was measured and signal densities were analyzed as
compared to controls (Fig. 1). Although there was a tendency of
total DJ-1 levels to increase slightly with higher UPDRS score,
statistical significance was not achieved.
Identification of DJ-1 isoforms in whole blood samples. Next, we
asked whether isoforms of DJ-1 could be used as biomarkers of PD
diagnosis or PD severity. DJ-1 is a low abundance protein and co-
migration of proteins is a well-known phenomenon in two-
dimensional electrophoresis (2-DE) analysis20. Thus, it is difficult
to detect DJ-1 unequivocally by MS in whole blood with 2-DE
separation when unfractionated samples are used. For this reason,
total DJ-1 (MW,19.9 kDa) was enriched using differential solubili-
zation (DS)methods before being submitted toMS for identification.
Multiple isoforms (2-DE spots) of DJ-1 at approximately 20 kDa and
a pH range of about 5–7were identified by silver staining andwestern
blotting using an anti-DJ-1 antibody (Fig. 2A, Inset; and Supple-
mental Fig. 1). We confirmed 7 spots to be isoforms of DJ-1 by LC-
LTQ-Obitrap MS (Table 3). Representative spectra from two
matched peptide masses (MH11675.8035 and MH1 1259.8259)
are shown in Fig. 2. Although the nature of each DJ-1 isoform
remains to be characterized, these isoelectric variants are believed
to result from PTMs that alter the intrinsic charge of the protein.
Indeed, 4-HNEmodifications at Lys-32 were identified in isoforms 4
and 6 (MH1 1212.7881, Fig. 3A) and at Lys-62 in isoform 6 (MH1
687.8409, Fig. 3B) in at least two independent experiments withmass
errors as low as 0.278 ppm. To further confirm these modifications,
western blotting using an antibody against HNEwas performed after
DS enrichment and 2-DE (Fig. 3A, Inset), and then the HNE-
positive spots were confirmed to be DJ-1 after re-probing with the
anti-DJ-1 antibody. Similar results were obtained when proteins
were enriched with IP before 2-DE and western blotting (Supple-
mental Fig. 2A and 2B). Additional modifications identified by
LTQ-Oribitrap MS included cysteic acid modification of isoform 4
at Cys-106 and phosphorylation of isoforms 4, 5 and 6 at Thr-19
(Fig. 3C,Table 3). The phosphorylatedDJ-1 isoformwas also further
confirmed by IP of a much larger volume of blood (4 mL) before 2-
DE and western blotting using an anti-phospho-Thr antibody
(Supplemental Fig. 2C and 2D). Besides these PTMs, methionine
sulfoxide modifications were also found at Met-17 and Met-26 in
different spots.
DJ-1 isoforms in PD vs. control blood samples. To investigate the
characteristics of DJ-1 isoforms in the diagnosis of PD or their corre-
lation with PD severity, the same comparison groups described for
total DJ-1 analysis were evaluated. At least 5 isoforms of DJ-1, named
as isoforms 2 through 6, were visualized in each group after western
blotting of the pooled whole blood samples (Fig. 4A). Of note, a
quantitative comparison of DJ-1 isoformswas performed in the sam-
ples without pre-enrichment. Isoforms were named in reference to
those shown in Fig. 2. The expression level of DJ-1 isoforms vs. total
DJ-1 level for each group was measured and quantified as volume
percentage (Fig. 4B). As compared to controls, the results showed
that isoform 2 was significantly decreased in AD and all stages of PD.
Conversely, isoform 6 was significantly increased in AD and slightly
increased in all stages of PD as compared to controls. However, none
of the isoforms showed clear correlation with PD severity. No signifi-
cant changes were observed among isoforms 3, 4, or 5 (Fig. 4C and 4D).
Discovery of HNE-modified DJ-1 isoforms in PD vs. control
blood samples. Among four major PTMs identified by MS
(methionine oxidation, which could be an ex vivo artifact, cysteine
oxidation, phosphorylation, and HNE adduction), HNE adduction
was the only PTM that could be followed with an antibody specific
and sensitive enough in our platform. The specificity of the antibody
against reduced HNE adducts15 was confirmed by dot blotting of
HNE-modified BSA and DJ-1 and 2-DE western blotting of whole
blood samples with or without reduction by NaBH4, using the anti-
HNE antibody or pre-immunity serum (Supplemental Fig. 3). To
further investigate HNE-altered DJ-1 among PD, AD, and control
samples, the level of HNE-modified DJ-1 fraction in each DJ-1
isoform or total HNE-modified DJ-1 was quantified. The HNE-
modified DJ-1 isoform 4 as a fraction of total isoform 4 level
(Fig. 5B) or as a fraction of total HNE-modified DJ-1 (isoform 4
1 6) level (Fig. 5C) tended to decrease as a function of PD severity,
with statistical significance achieved in patients with more advanced
diseases. In contrast, although the ratio of the expression of HNE-
modified isoform 6 over total isoform level did not change signi-
ficantly for any group (Fig. 5D), the ratio of isoform 6 as a fraction
of totalHNE-modified forms (Fig. 5E) was increased in late-stage PD
patients compared to early-stage PD patients, AD patients, and controls.
Validation of HNE-modified DJ-1 isoforms in PD vs. control
blood samples. To further confirm the HNE-modified DJ-1 result
Table 1 | Blood group data of patients and controls for discovery
Sample Group Cases Age (Mean 6SD) M:F UPDRS (Mean 6SD)
Control 1 10 64.2 6 8.417 654
2 10 64.2 6 9.760 654
3 10 64.3 6 7.379 654
AD 1 4 67.8 6 7.823 252
2 5 67.8 6 8.955 352
3 5 67.4 6 6.768 253
PD (UPDRS ,15) 1 5 63.6 6 9.236 253 12.0 6 5.339
2 5 62.6 6 11.104 253 10.1 6 3.232
3 5 63.2 6 11.520 253 11.2 6 3.565
PD (UPDRS 15–30) 1 10 63.8 6 7.146 654 20.7 6 4.714
2 10 63.8 6 4.517 654 21.5 6 3.154
3 10 63.8 6 7.254 654 21.6 6 4.122
PD (UPDRS .30) 1 10 72.6 6 8.302 654 47.6 6 9.095
2 10 71.5 6 8.357 654 47.2 6 8.417
3 10 72.2 6 8.804 654 47.6 6 7.720
Total 119
www.nature.com/scientificreports
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in PD patients, a validation study of 114 subjects including controls
(n530) and patients with early- (n524), intermediate- (n530), and
late-stage PD (n530) was performed. As indicated in Fig. 5, the
general tendencies of HNE-modified DJ-1 isoforms 4 and 6 are
consistent in comparing the discovery and validation cohorts.
HNE-modified isoform 4 as a fraction of both isoform 4 level
(Fig. 5B) and total HNE-modified DJ-1 (Fig. 5C) tended to
decrease in both cohorts. Importantly, statistical significance was
achieved in both cohorts when comparing late-stage PD with
controls or early-stage PD. This isoform also exhibited a
‘‘progressive’’ characteristic, with decreasing expression of the
HNE-modified form of the isoform associated with increasing
disease severity. Additionally, while HNE-modified isoform 6
exhibited no correlation with disease as a fraction of total isoform
6 level (Fig. 5D), it was found to be increased as a fraction of total
HNE-modified DJ-1 when comparing controls and early-stage PD
patents to intermediate- and late-stage PD patients (Fig. 5E).
Discussion
Several interesting findings were made as a result of the present
study. First, similar to what we described in plasma, total DJ-1 levels
in whole blood were not changed significantly in either AD or PD
patients compared with age-matched controls. Second, 7 isoforms of
DJ-1 in whole blood were identified, with several PTMs within those
isoforms, including phosphorylation and oxidative modifications.
Most importantly, we observed significant neurodegenerative dis-
ease-related differences in the whole blood levels of two of these
isoforms, with HNE adduction, that were unique to PD diagnosis
or disease severity.
As discussed earlier, unlike CSF, total DJ-1 in plasma is not an
effective marker for differentiating PD patients from controls and is
not correlated with PD severity12. More than 95% of blood DJ-1 is
contained in RBCs12, and variable in vitro or in vivo hemolytic
changes that are beyond investigators’ control likely contributed to
contradicting reports in the literature regarding its plasma levels12,21–23.
Our study has the advantage that it was carried out in whole blood,
eliminating the possibility of confounding by component contam-
ination. The results of our study, which used quantitative western
blotting, are in accordance with the findings that total DJ-1 levels in
blood do not change based on neurodegenerative disease status. This
observation further indicates that total DJ-1 is not a useful biologic
indicator of PD in blood or in blood components.
In contrast to total DJ-1 levels, we found that some isoforms in
whole blood samples were significantly different in both PD and AD
patients when compared with controls. Specifically, isoform 2 was
lower in both PD and AD patients, while isoform 6 was higher in
both disease groups. However, while these DJ-1 isoforms may have
potential as biomarkers of neurodegenerative disease, neither iso-
form exhibited specificity for either disease nor did these correlate
with PD severity. It should be noted that the inability to differentiate
AD and PD patients based on these isoforms does not necessarily
negate the potential clinical utility of these candidate biomarkers, as
AD and PD are easily distinguishable by clinicians using current
diagnostic methods. A more important question to ask in future
research is whether DJ-1 isoforms can distinguish PD from other
parkinsonian conditions that overlap with PD clinically, such as
multiple system atrophy and progressive nuclear palsy. The dia-
gnosis of PD and disease progression monitoring are currently
mainly based on the evaluation of clinical symptoms, which is sub-
jective and thus often associated with a considerable error rate. More
recently, several neuroimaging techniques may be employed to help
clinicians in assessing PD and its progression24. However, there are
several notable limitations to these techniques, including limited
specificity and accountability for compensatory mechanisms. It is
therefore vital that biochemical markers such as the ones described
here as well as more robust specific ELISA and Luminex assays
continue to be developed in an effort to complement the inherent
shortcomings of neuroimaging biomarkers.
Figure 1 | Total DJ-1 levels in whole blood were not significantly different among patients with PD at various stages, AD, and controls. Pooled whole
blood samples from controls, patients with Alzheimer disease (AD) and patients with Parkinson disease (PD) at various stages (UPDRSmotor score,15,
15–30, and.30) were analyzed by 1-DE western blotting. The samples were pooled according to Table1 (five comparison groups with each pooled into
three sub-groups). (A) Coomassie R-350 staining of the membrane indicated equal loading among the five samples. This is a representative result from
one sub-group of three independent experiments. (B) Quantitative western blotting against DJ-1 of the 5 groups indicated total DJ-1 does not
significantly change with disease status. The adjusted DJ-1 band volumes were normalized to the control values in each independent experiment/gel. A
representative gel is shown in (C).
www.nature.com/scientificreports
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Another major discovery of our investigation relates to the char-
acterization of various PTMs of DJ-1 with MS and western blotting.
Although methionine oxidation can occur ex vivo during sample
processing (i.e., its significance is unclear) and phosphorylation
has been reported at Tyr-6725, both phosphorylation at Thr-19 and
HNE adduction of DJ-1 are novel and potentially important to PD
pathogenesis in addition to their utility as biomarkers. To this end, it
should be stressed that oxidatively modified DJ-1 has been reported
to be elevated in brain tissues of both PD and AD patients26, and
oxidized DJ-1 protein has been previously suggested to be a useful
biomarker as it has been recently demonstrated that levels of DJ-1
oxidation at Cys-106 are elevated in the RBCs of unmedicated PD
patients when compared to both medicated patients and controls27.
Several investigations clearly suggest that the Cys-106 oxidative
modification is critically involved in PD pathogenesis28–31. The issue,
of course, is whether observations in the CNS are related to peri-
pheral modifications of DJ-1. While this question cannot be
answered by the current study alone, cysteine-sulfonic acid modi-
fication of Cys-106 in isoform 4 was indeed observed in the current
investigation. Importantly, this modification was not observed in the
muchmore abundant isoform 6, suggesting this highly relevant PTM
may be specific to a distinct DJ-1 isoform. Additionally, in vivo
studies demonstrate that dosing rats with the neurotoxicants 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine or 6-hydroxydopamine
results in elevated levels of Cys-106 oxidized DJ-1 in RBCs32, indi-
cating that the modification in blood DJ-1 may not only be a sur-
rogatemaker, but also be biologically relevant to PD. It should also be
stressed that one of the prevailing schools of thought is that PD is not
just a CNS disease as it has a significant peripheral component,
including generalized mitochondrial dysfunction in platelets, con-
stipation, and cardiac arrhythmia due to denervation of the auto-
nomic nervous system.
HNE modification of DJ-1, though not reported previously even
in the CNS, is clearly consistent with the generally accepted hypo-
thesis that PD patients experience substantially increased levels of
oxidative stress, with multiple proteins containing HNE adduc-
tion33,34. The fact that HNE-modified DJ-1 isoform 4 significantly
decreased, while isoform 6 increased, in late-stage PD patients sug-
gests that these modified DJ-1 isoforms could potentially be biomar-
kers of disease severity in a body fluid that is readily accessible
clinically. The on-state UPDRS motor score was selected as an index
of PD severity in this study, as it has been utilized effectively to reflect
Figure 2 | DJ-1 isoforms in whole blood were confirmed by MS/MS and western blotting. (A) 2-DE western blotting against DJ-1 identified 7 spots as
DJ-1 isoforms (Inset). LTQ-Obitrap MS/MS confirmed the 7 spots to be DJ-1. Shown is a MS2 spectrum of MH1 1675.8035 indicating a DJ-1 peptide
with the sequence GAEEMETVIPVDVMR. (B) MS2 spectrum indicating MH1 1259.8259 is a DJ-1 peptide with the sequence DVVICPDASLEDAKK.
www.nature.com/scientificreports
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clinical progression of motor impairments in patients with PD; in
both the discovery and validation cohorts, patients with higher
UPDRS motor scores also tended to have longer duration of disease,
another commonly used indicator of the disease severity. However, it
should be noted that both indices used to stage PD patients are prone
to several limitations that may lead to misclassification bias. For
UPDRS motor scores, these include differential benefit from levo-
dopa, physician biases in treatment, subject expectations, and non-
motor signs which contribute substantially to disability. Similarly,
disease duration can only partially reflect the disease severity or
progression.
The molecular mechanisms underlying quantitative alterations of
different DJ-1 isoforms remain to be characterized. One possibility is
that HNE-modified DJ-1 (indicative of damaged protein) is targeted
for degradation more readily by proteasome or lysosome systems,
resulting in a decrease of isoform 4. Such a phenomenon has been
demonstrated in vitrowhere it has been found thatHNE can decrease
DJ-1 levels and induce cell death in HT22 cells35. However, the pro-
cess could be much more complicated, given that the opposite trend
was observed for isoform 6. A more likely explanation could be that
there is a PD-specific shift of HNE-modification fromDJ-1 isoform 4
to 6 as the disease progresses, a hypothesis that needs to be tested in
future investigations.
TwoHNE-modified peptides were identified with high confidence
in this study; for example, we were able to measure the mass of D-V-
V-I-C-P-D-A-S-L-E-D-A-K(HNE) to be within a 0.278 ppm mass
error compared to theoretical values using an LTQ-Orbitrap.
However, the two reported peptides consist of a mis-cleavage (N-
flanking sequence: -R-A-G-) and a modified C-terminal (C-flanking
residue: -K-), respectively. There are a few potential underlying rea-
sons that may result in proteolytic miscleavage and/or modified
terminals, including protein structure, enzymatic impurities, and
post-tryptic mechanisms such as chemical hydrolysis. The MS data
suggest that these two locations represent the strongest candidate
sites of HNE-modification. Given that we have also confirmed the
existence of HNE modifications in the 2-DE gel spots using western
blotting after both the DS and IP enrichments, it is reasonable to
conclude that HNE-modified proteins exist in these samples.
It should also be noted that although several novel PTMs were
identified in the current investigation, the migration pattern cannot
necessarily be explained by the identified PTMs alone. A recent meta-
analysis of the DJ-1 2DE literature indicated acidic isoforms of the
Table 3 | Identification of modified DJ-1 isoforms in human whole blood by mass spectrometry
Spot No. Coverage (%) Confidence PTM site Modification peptide sequence Probability Ions
1 25.4 1.000 M17 GAEEMdETVIPVDVMR 1.0000 20/28
M26 GAEEMETVIPVDVMdR 0.9999 18/28
M17,M26 GAEEMdETVIPVDVMdR 1.0000 21/28
2 16.4 1.000 M17 GAEEMdETVIPVDVMdR 0.8975 13/28
3 37.1 1.000 M17 GAEEMdETVIPVDVMR 1.0000 19/28
M26 GAEEMETVIPVDVMdR 1.0000 17/28
4 57.1 1.000 K32 IKaVTVAGLAGK 1.0000 16/20
T19 GAEEMETbVIPVDVMR 0.9262 11/28
C106 GLIAAICcAGPTALLAH 0.9979 21/30
M26 GAEEMETVIPVDVMdR 1.0000 16/28
M17 GAEEMdETVIPVDVMR 1.0000 18/28
5 31.2 1.000 T19 GAEEMETbVIPVDVMR 0.9979 12/30
M17 GAEEMdETVIPVDVMR 1.0000 17/28
M26 GAEEMETVIPVDVMdR 0.9999 13/28
6 43.9 1.000 K32 IKaVTVAGLAGK 1.0000 17/20
T19 GAEEMETbVIPVDVMR 0.9998 17/28
K62 DVVICePDASLEDAKa 1.0000 18/26
M17 GAEEMdETVIPVDVMR 1.0000 18/28
M26 GAEEMETVIPVDVMdR 1.0000 18/28
M17,26 GAEEMdETVIPVDVMdR 1.0000 17/28
7 23.3 1.000 M26 GAEEMETVIPVDVMdR 1.0000 15/28
M17,26 GAEEMdETVIPVDVMdR 1.0000 16/28
Note: a, 4-Hydroxynonenal (HNE); b, Phosphorylation; c, Cysteic acid; d, Methionine sulfoxide; e, Carbamidomethyl.
Table 2 | Blood group data of patients and controls for validation
Sample Group Cases Age (Mean 6SD) M:F UPDRS (Mean 6SD)
Control 1 10 63.0 6 11.431 654
2 10 63.8 6 7.729 654
3 10 63.6 6 8.872 555
PD (UPDRS ,15) 1 8 65.5 6 7.164 454 10.4 6 3.777
2 8 56.3 1 8.678 454 11.1 6 2.295
3 8 57.7 6 6.632 454 11.6 6 1.598
PD (UPDRS 15–30) 1 10 62.6 6 8.653 654 21.8 6 4.781
2 10 62.1 6 4.156 654 22.2 6 5.095
3 10 62.8 6 7.323 654 21.6 6 4.300
PD (UPDRS .30) 1 10 72.1 6 8.084 654 46.3 6 8.509
2 10 71.1 6 9.692 654 45.4 6 9.300
3 10 71.3 6 7.678 654 46.8 6 11.708
Total 114
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Figure 3 | 4-HNE and phosphorylation modifications of DJ-1 in whole blood were identified by MS/MS. (A) Western blotting confirmed HNE
modification of DJ-1 isoforms. The right-hand inset shows HNE western blotting before stripping of the DJ-1 membrane. Left, LTQ-Obitrap MS/MS
spectrum indicated MH1 1212.7881 is a DJ-1 HNE-modified peptide in spots 4 and 6 at Lys-32. (B) MS2 spectrum indicated MH1 687.8409 is a DJ-1
HNE-modified peptide in spot 6 at Lys-62. (C) MS2 spectrum indicated MH1 1771.7635 is a DJ-1 phosphorylation-modified peptide in isoforms 4, 5
and 6 at Thr-19.
www.nature.com/scientificreports
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protein become more prominent in subjects with neurodegenerative
disorders36. The MS-identified phosphorylation, 4-HNE, and various
other oxidation modifications are expected to lower the proteins pI,
which would shift its 2D spot toward the more acidic end of the
gel29,37–40. However, it is likely that there are many other PTMs that
remain to be identified and it is the net effect of all of these mod-
ifications taken together that ultimately determines an isoform’s pI.
Examples of additional potentially unidentified modifications that
can influence pI include glycosylation, acetylation, deamidation, and
glutathionylation39,41. In fact, one of the major challenges of MS
identification of peptides and proteins is that a significant portion
of peptides cannot be recognized without a known mass shift.
Additionally, the relative abundance of peptide sequences containing
signature PTMs responsible for an isoform’s pI shift may be too low
to be detected without substantial enrichment of the specific modi-
fied form. Furthermore, biologically modified peptides may undergo
a series of ex vivo modifications during sample preparation which
compromise the integrity of the original peptide thus preventing its
identification.
It has been demonstrated that dopamine treatment in human SH-
SY5Y neuroblastoma cells may cause a DJ-1 ‘‘isoform shift’’ toward
more acidic pIs42, raising the possibility that HNE-modified DJ-1 in
our study could be influenced by dopamine treatment of PD patients.
However, wewere unable to observe such a shift of total levels of DJ-1
isoforms in human whole blood (Fig. 4); furthermore, the HNE-
modified isoforms of interest reported here (#4 and #6) are localized
on themore basic end of theDJ-1 pI range.We also incubated human
whole blood with dopamine and did not observe themodifications of
interest (Suppl. Fig. 4). It is therefore highly unlikely dopamine
therapy in PD patients is capable of inducing the 4-HNE modified
DJ-1 changes observed in this study.
In summary, we have confirmed that measurement of total DJ-1
in blood is not suitable for distinguishing PD or AD patients from
age-matched controls. Furthermore, we identified 7 isoforms of DJ-
1 in whole blood samples, several of which contain newly described
PTMs in addition to the previously characterized Cys-106 oxida-
tion. The blood levels of two of these isoforms appeared to be
significantly altered in both PD and AD patients as compared to
controls. Most significantly, we have found that the ratio of the 4-
HNE-modified fraction of two of these isoforms increases with
respect to both PD diagnosis and PD severity, a finding which
was further confirmed in an independent population. These find-
ings provide an indication of the diagnostic potential of DJ-1 iso-
forms in whole blood. These results, of course, need to be validated,
ideally using ELISA or Luminex technology that can readily mea-
sure individual samples.
Figure 4 | The expression of DJ-1 isoforms was significantly different among control and disease whole blood samples. (A) 2-DE western blotting of
DJ-1 isoforms in different pooled whole blood samples (Table 1); this is a representative result from one of the three sub-groups of three independent
experiments. (B) Quantification of 2-DE western blotting against DJ-1; the adjusted DJ-1 isoform volumes over total DJ-1 levels were normalized to the
control values in each independent experiment. Means 6 SEM are shown. (C) Quantification of DJ-1 isoform 2 (DJ-1 isoform 2/total DJ-1) among
control and disease whole blood samples; (D) Quantification of DJ-1 isoform 6 (DJ-1 isoform 6/total DJ-1) among control and disease whole blood
samples. Asterisks denote data points representing an experimental group significantly different statistically (*p,0.05, **p,0.01, ***p,0.001) from the
control group.
www.nature.com/scientificreports
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Figure 5 | The expression of HNE-altered DJ-1 isoforms was significantly different in whole blood samples obtained fromAD patients, PD patients at
various stages, and controls in discovery and validation cohorts. (A) 2-DE western blotting of HNE-modified DJ-1 isoforms in pooled whole blood
samples. Left, blotting using an anti-HNE antibody; right, the same membrane was stripped and re-probed with an anti-DJ-1 antibody.
(B)–(E)Quantification of 2-DEwestern blotting of DJ-1 isoforms 4 and 6 in discovery (solid bars) and validation set (open bars): HNE-modified isoform
4 as a relative fraction (mean 6 SEM) of total isoform 4 (HNE-isoform 4/DJ-1 isoform 4 total) (B) and of total HNE-modified DJ-1 (HNE-isoform 4/
[HNE-isoform 41 6]) (C), HNE-modified isoform 6 as a relative fraction (mean6 SEM) of total isoform 6 (D) and of total HNE-modified DJ-1 (E); the
values in each independent experiment were normalized to the values of the control group. (* indicates p,0.05; ** indicates p,0.01).
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Methods
Participants. Subjects for both the discovery (119 total; 30 controls, 14 AD patients,
75 PD patients) and validation (114 total; 30 controls, 84 PD patients) studies were
recruited from the Veterans Affairs Puget Sound Health Care System at Seattle and
Washington University (St. Louis, MO). All participants provided informed consent
and underwent evaluation by a neurologist that consisted of a structured interview,
neurological examination, laboratory tests, and neuropsychological assessments. All
control subjects were community volunteers who hadMiniMental State Exam Scores
.27, paragraph recall scores.6, no history of neurological disease, and no history or
evidence of cognitive or functional decline. The clinical diagnosis of probable ADwas
made using NINDS-ADRDA criteria13, applied at a clinical consensus conference in
the Clinical Core of the University of Washington Alzheimer’s Disease Research
Center. All PD patients met UK PD Society Brain Bank clinical diagnostic criteria for
PD14. PD patient samples were further categorized based on UPDRS Part III on-state
motor scores to approximate disease stage. To correlate the performance of DJ-1 with
PD severity, patients with UPDRS scores,15 were defined as having early-stage PD,
those with scores ranging from 15–30 were classified as middle-stage PD, while those
with scores .30 were classified as late-stage PD patients. Demographic data for all
subjects and UPDRS scores for all PD patients used in the study are listed in Table 1
(discovery set) and Table 2 (validation set). The study was approved by the
Institutional Review Boards of all participating institutions.
Whole blood sample preparation. After adding 10% protease inhibiting cocktail,
130 mL of whole blood from each individual sample were pooled according toTable 1
and Table 2. The pooled samples were lysed by adding an equal volume of lysis buffer
[20 mMTris (pH 7.5), 150 mMNaCl, 1 mMEDTA, 1 mMEGTA, 1%Triton X-100,
2.5 mM sodium pyrophosphate (Na4P2O4), 1 mM b-glycerophosphate, 1 mM
sodium orthovanadate (Na3VO4) and 1 mg/mL leupeptin], vortexed for 2 min,
placed on ice for 5 min, and vortexed again for 2 min. After freezing at 280uC for at
least 30 min, the samples were thawed in a 37uC water bath for 2–3 min and then
vortexed for 2 min and centrifuged at 14,0003g for 10 min at 4uC. The supernatant
was then transferred to a new tube and either stored at 280uC or immediately used.
Differential solubilization (DS) methods to enrich DJ-1. Low molecular weight
proteins, including DJ-1, were enriched from whole blood according to a procedure
described previously15,16, with the following slight modifications: 50 mL whole blood
samples were diluted with 100 mL denaturating solution [7 Murea, 2 M thiourea, and
20 mM dithiothreitol (DTT)] and precipitated with 4.5 mL acetone while mixing at
4uC for 1 h, then centrifuged at 19,0003g for 15 min at 4uC. The pellet was resolved
in 1 mL 70% acetonitrile (ACN) containing 12 mM HCl and mixed at 4uC for 1 h.
After centrifuging at 19,0003g for 15 min at 4uC again, the supernatant was dried
down using a CentriVap Concentrator (Labconco, Kansas City, MO, USA),
resuspended in 200 mL 2-DE rehydration and lysis buffer [8 M urea, 50 mM DTT,
2% (w/v) CHAPS, 0.2% (w/v) carrier ampholytes, and 0.0002% bromophenol blue],
and stored at 280uC until use.
Immunoprecipitation. Immunoprecipitation (IP) was carried out using either
InvitrogenM-280 Tosylactivated Dynabeads (Carlsbad, CA, USA) (for HNEDJ-1) or
Santa Cruz ImmunoCruz IP/WB Optima F System (Santa Cruz, CA, USA) (for
phosphorylated DJ-1) with slight modifications to the manufacturer’s instructions.
Briefly, for HNE DJ-1 detection, 40 mg of dialyzed anti-DJ-1 antibody (Novus,
Littleton, CO, USA) were coupled with 40 mL Dynabeads and then incubated with
1 mL of lysed whole blood (diluted 151 in PBS) at 4uC overnight. For phosphorylated
DJ-1 detection, 1 mL matrixF was coupled to 100 mg antibody and incubated with
4 mL whole blood. Following incubation, beads were washed 3 times with PBS and 1
time withMilli-Q water and then incubated in 100 mL of 2-DE rehydration buffer for
2320 min. The supernatants were then combined and used for subsequent 2-DE
western blotting analyses.
Two-dimensional electrophoresis. The 2-DEs were performed as described
previously17. Briefly, for first-dimension electrophoresis, 2 mL lysed blood or enriched
samples were resolved in 200 mL rehydration buffer and applied to an 11-cm pH 4–7
ReadyStripTM IPG strip (Bio-Rad, Hercules, CA, USA) for rehydration at room
temperature for 20 h, then isoelectric focusing (IEF) was performed using a
PROTEANH IEF cell (Bio-Rad) at 250-V linear ramp for 1 h; 500-V rapid ramp for
1 h; 1000-V rapid ramp for 1.5 h; 8000-V linear ramp for 5 h; 8000-V rapid ramp for
a total of 35,000 volt-hours; and 500-V rapid ramp as a holding step for additional
volt-hours (typical total volt-hours are,62,000). All the processes above were carried
out at 20uC with a current limit of 50 mA per IPG strip.
For second-dimension electrophoresis, IPG strips were equilibrated for 10 min in
buffer I [37.5 mM Tris-HCl (pH 8.8) containing 6 M urea, 2% w/v SDS, 20% v/v
glycerol, and 2% DTT] and then re-equilibrated for 10 min in buffer II [same buffer
containing 2.5% iodoacetamide in place of DTT]. For the HNE immunoblotting
process, IPG strips were soaked in 0.1 M Tris HCl (pH 8.5) containing 0.86 mM
EDTA and 100 mM NaBH4 (Sigma-Aldrich, St. Louis, MO, USA) for 15 min then
washed in the same buffer without NaBH4 for 15 min before equilibration with DTT
and iodoacetamide. Second-dimension electrophoresis (SDS-PAGE) was performed
using 10–20% Precast Criterion Tris-HCl linear gels (Bio-Rad) with a constant
voltage of 120 V for 10 min then 160 V for 70 min until the dye front reached the
bottom of the gels. Silver staining was used to visualize 2-DE spots to be excised.
Western blotting and quantification.Western blotting on 2-DE gels was performed
as previously described18. Briefly, gels containing samples were transferred to a PVDF
membrane for 2 h at 800 mA in transfer buffer [48 mM Tris, 39 mM glycine, and
15% methanol] at 4uC. For HNE-modified protein detection, membranes were
blocked in Tris buffered saline (pH 8.0) containing 0.1% (v/v) Tween (TBS-T) and 5%
(w/v) bovine serum albumin (BSA) at room temperature for 1 h and then incubated
overnight at 4uC with a rabbit anti-reduced HNE antibody15 at a dilution of 151000.
After washing with TBS-T, the membranes were incubated with horseradish
peroxidase-conjugated goat anti-rabbit antibody at a dilution of 1520,000 in TBS-T
containing 3% (w/v) BSA at room temperature for 1 h. The immunostained proteins
were detected using ECL Plus (GE Healthcare, Buckinghamshire, UK) and exposed
for 2 min. The developed films were scanned using a VersaTM DOC Image System
Model 3000 and analyzed with PDQEST 7.0 software (Bio-Rad, Hercules, CA, USA).
For phosphorylated threonine protein detection, membranes were blocked in 5%
(w/v) BSA/TBS-T and then washed twice with TBS-T and once with TBS. The
membrane was then incubated with themouse anti-Phospho-Threonine antibodyQ7
(Qiagen, Valencia, CA, USA) (diluted 15100 in TBS-T) overnight at 4uC, followed by
rabbit anti-mouse secondary antibody (diluted 1520,000 in 10%non-fatmilk/TBS-T)
for 1 h at room temperature. For total DJ-1 western blotting, the blocking buffer was
5% (w/v) non-fat milk in TBS-T, the primary antibody was a rabbit anti-DJ-1 anti-
body (Novus) diluted 152000, and the secondary antibody and dilutionwere the same
as described above. The PVDFmembranes were stained byCoomassie R-350 to verify
equal loading.
Mass spectrometry. Spots identified using DS-enriched methods were excised from
sliver stained 2-D gels according to the 2-DE western blotting result, digested with
trypsin, and analyzed by LTQ-Orbitrap MS as previously described19. Briefly, target
spots were excised and placed in a 1.5-mL plastic microcentrifuge tube, washed with
MilliQ water three times, followed by 50% ACN several times, and dried in a vacuum
centrifuge. The gel pieces were digested with 20 mL of 20 ng/mL sequencing grade
trypsin (Promega, San Luis Obispo,CA,USA) in 50 mMammonium bicarbonate (pH
8.0) for 16 h at 37uC. The peptides were then extracted once in 30 mL of 50 mM
ammoniumbicarbonate and twice in 30 mL extraction buffer [50% (v/v) ACN and 5%
(v/v) formic acid], with 10 min incubation and occasional gentle vortex mixing each
time. The supernatants saved from each extraction were combined, dried down, and
reconstituted in buffer containing 5% ACN and 0.1% formic acid.
The protein identification was performed using a LTQ-Orbitrap hybrid MS
(Thermo Scientific, San Jose, CA, USA) with the following conditions: Peptides were
separated online with 0.75 mm i.d. 320 cm home-packed columns (100A˚ Magic
C18AQ: Michrom Bioresources, Auburn, CA, USA) with a 60 min 5–35% ACN/
water gradient containing 0.1% formic acid using a Nano-Acquity UPLC (Waters,
Milford, MA, USA). The electrospray voltage was applied via a liquid microtee
junction located in between the precolumn and analytical column. All ions were
measured in positive mode and automatic gain control was optimized to maintain
constant ion populations. After data dependent acquisition, tandem MS data was
searched by SEQUEST (v27) against the International Protein Index human protein
database (v3.68) and protein identifications were filtered using PeptideProphet. All
methionines were allowed to be oxidized and cysteine residues were considered as
being alkylated by iodoacetamide and were assigned a mass of 160 Da. The lysine,
histine, and cysteine resides were set as being 4-HNE modified with a mass of
1156 Da. The threonine, tyrosine, and serine residues were set as being phos-
phorylated with a mass of 180 Da. The cysteine residues also were set as being
oxidized to cysteic acid with a mass of 148 Da.
Statistical analysis. All the western blotting data were collected from at least three
independent experiments and analyzed using Prism 4.0 (Graphpad, San Diego, CA,
USA). Group differences were assessed using one-way analysis of variance (ANOVA)
followed by the post-hoc Tukey honestly significant difference test. Asterisks denote
data points representing an experimental group significantly different statistically
(p,0.05) from the control group.
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